Suppr超能文献

抗癫痫药物的选择:一线附加治疗共识文件。

Selection of antiseizure medications for first add-on use: A consensus paper.

机构信息

Institute of Neurology, University Magna Graecia Catanzaro, Italy.

IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

出版信息

Epilepsy Behav. 2021 Sep;122:108087. doi: 10.1016/j.yebeh.2021.108087. Epub 2021 Jun 24.

Abstract

INTRODUCTION

When monotherapy used alone or sequentially fails to achieve seizure control, a trial of combination therapy may be considered.

OBJECTIVE

To define optimal criteria to guide choice of an antiseizure medication (ASM) for use as first add-on.

METHODS

A standardized Delphi procedure was applied to produce a list of consensus statements. First, an Expert Board consisting of 5 epileptologists agreed on a set of 46 statements relevant to the objective. The statements were then finalized through an iterative process by a Delphi Panel of 84 Italian pediatric and adult neurologists with expertise in the management of epilepsy. Panel members provided anonymous ratings of their level of agreement with each statement on a 9-point Likert scale.

RESULTS

Consensus, defined as agreement by at least 80% of Panel members, was reached for 36 statements. Medication-related factors considered to be important for drug selection included efficacy, tolerability and safety, interaction potential, mechanism of action, and ease of use. The need to optimize adherence and to tailor drug selection to individual characteristics was emphasized.

CONCLUSIONS

Choice of an ASM for first add-on requires consideration of many factors, many of which also apply to choose initial treatment. Factors more specifically relevant to add-on use include drug interaction potential and the preference for an ASM with a different mechanism of action.

摘要

简介

当单药治疗单独或序贯治疗未能控制癫痫发作时,可能会考虑联合治疗试验。

目的

定义最佳标准,以指导选择抗癫痫药物(ASM)作为首选附加治疗。

方法

采用标准化德尔菲程序制定共识声明清单。首先,由 5 名癫痫专家组成的专家委员会就与目标相关的 46 项声明达成一致。然后,通过意大利儿科和成人神经病学专家组成的 84 名德尔菲小组的迭代过程对这些声明进行最终确定,这些专家在癫痫管理方面具有专长。小组成员对每个声明的同意程度在 9 分李克特量表上进行匿名评分。

结果

至少 80%的小组成员达成共识,即 36 项声明达成共识。药物相关因素被认为是药物选择的重要因素,包括疗效、耐受性和安全性、相互作用潜力、作用机制和易用性。强调需要优化依从性,并根据个体特征调整药物选择。

结论

首选附加治疗的 ASM 选择需要考虑许多因素,其中许多因素也适用于初始治疗的选择。更具体地与附加使用相关的因素包括药物相互作用潜力和对具有不同作用机制的 ASM 的偏好。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验